SLC5A2 and diabetes mellitus: In addition, patients with FRG provide an ideal model for identifying and investigating the pathogenic variants of SLC5A2. SGLT2 inhibitors have attracted attention as therapeutic agents for type 2 diabetes in recent years1, and the analysis of the SLC5A2 gene and examination of the pathophysiology of FRG could provide useful clues to the progress of diabetes and its treatment.